1.Recent Advances in Anti-Obesity Agents.
Korean Journal of Medicine 2018;93(6):501-508
Obesity is a chronic disorder that is a significant risk factor for diabetes, cardiovascular diseases, malignancy, and other chronic diseases. Lifestyle modifications form the basis of most treatments for obesity, but it has become clear that such modifications alone are not enough for many obese patients. When a behavioral approach is insufficient, pharmacological treatment may be recommended. In recent years, the US Food and Drug Administration (FDA) has withdrawn several therapeutic options for obesity due to their side effects, but has approved four novel anti-obesity agents. Until recently, orlistat was the only drug approved for the management of long-term obesity, but the US FDA approved the novel anti-obesity drugs lorcaserin and phentermine/topiramate in 2012, and naltrexone/bupropion and liraglutide in 2014. The present review discusses the different pharmacotherapeutic options for the treatment of obesity.
Anti-Obesity Agents*
;
Cardiovascular Diseases
;
Chronic Disease
;
Humans
;
Life Style
;
Liraglutide
;
Obesity
;
Risk Factors
;
United States Food and Drug Administration
2.Medical Management of Obesity.
The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2017;17(2):66-71
We, as health advocates, aim to raise awareness on the importance of a long-term approach for managing obesity as a chronic disease rather than merely a cosmetic issue. The cornerstone of obesity management remains the application of comprehensive lifestyle programs designed to modify dietary habits, physical activity, and behavior. Drug therapy for obesity should be used in addition to comprehensive lifestyle management. Appropriate use of anti-obesity drugs, approved by Food and Drug Administration, may help patients with obesity. Therefore, clinicians need to follow both a comprehensive and a personalized approach to treat obesity. Initially, it is necessary to assess patient's readiness to lose weight and to elicit the reasons and motivations for weight loss. Then, realistic goals should be set based on the patient's health status. The goals include reducing and preventing comorbidities related to obesity. Even a modest weight loss, such as 5~10% of total body weight, can significantly improve metabolic health. Finally, both the patient and the physician should be aware that weight maintenance is as important as weight loss.
Anti-Obesity Agents
;
Body Weight
;
Chronic Disease
;
Comorbidity
;
Diet
;
Drug Therapy
;
Food Habits
;
Humans
;
Life Style
;
Motor Activity
;
Obesity*
;
Practice Management
;
United States Food and Drug Administration
;
Weight Loss
3.Pharmacotherapy for obesity.
Journal of the Korean Medical Association 2011;54(4):409-418
Due to its serious comorbidities and high prevalence, obesity is one of the heaviest burdens for public health. Although diet, exercise and behavioral modification are the first-line treatment for obesity, their outcomes are not satisfactory. The goal of this article is to review currently available anti-obesity drugs so that physicians may apply the principle of pharmacologic treatment for obesity to obese patients in the real clinical situation. Orlistat, phentermine, diethylpropion, mazindol, and phendimetrazine have been approved as anti-obesity drugs by Korea food and drug administration and administered to patients in Korea. Besides, several non-approved drugs, including fluoxetine, bupropion, topiramate and zonisamide, are being used for weight reduction. Among these drugs, orlistat has been studied most and is the only approved drug for long-term weight management. On the other hand, the rest of the approved drugs lack the evidence of safety issues on the long-term administration. Considering that the non-approved drugs have only a small body of clinical trial results for their efficacy and safety as anti-obesity drugs, it is not appropriate to use them as a first-line therapy in obesity. Because several new medicines and combination therapies are under investigations, more drug therapy options seem to be available in this field in coming years. Although the properly executed pharmacologic treatment is a good option for weight reduction, physicians should recognize that diet, exercise, and behavioral modification are essential to all obese patient and that pharmacologic treatment has several limitations until now.
Anti-Obesity Agents
;
Bupropion
;
Comorbidity
;
Diet
;
Diethylpropion
;
Fluoxetine
;
Fructose
;
Hand
;
Humans
;
Isoxazoles
;
Korea
;
Lactones
;
Mazindol
;
Morpholines
;
Obesity
;
Phentermine
;
Prevalence
;
Public Health
;
United States Food and Drug Administration
;
Weight Loss
4.Weight Loss Drugs Recently Approved by the FDA.
Journal of Korean Diabetes 2013;14(2):58-62
There have been many advances in obesity treatment, including life-style modification and pharmacological and surgical treatments. It seems that the most remarkable advances in obesity treatment are those of pharmacological strategies. However, weight loss medications have a long history of development. The FDA has withdrawn anti-obesity drugs such as fenfluramine, dexfenfluramine, and phenylpropylamine due to unwanted side effects. Sibutramine was voluntarily withdrawn from the market, and new drugs such as rimonabant have been suspended in the middle of clinical study due to unacceptable side effects. Last year, the FDA approved two new anti-obesity drugs for the treatment of obesity. Lorcaserin is a selective 5-hydroxytryptamine receptor 2c (5-HT2c) agonist whose pharmacological mechanism of action is similar to those of fenfluramine and dexfenfluramine. However, lorcaserin is specific for 5-HT2c, which is located almost exclusively in the CNS and is not found on heart valves. Three exciting phase 3 clinical trials for lorcaserin have been published recently. Lorcaserin has been shown to successfully result in weight reduction, and the drug was not found to lead to heart disease, as is the case with some other such drugs. Furthermore, the FDA also approved controlled release phentermine/topiramate (PHEN/TPM CR), a drug composed of immediate-release phentermine and controlled-release topiramate. Weight reduction by PHEN/TPM CR is better than any other anti-obesity drugs in the world. Along with this excellent efficacy, however, come painful side effects that clinicians should consider.
Anti-Obesity Agents
;
Benzazepines
;
Cyclobutanes
;
Dexfenfluramine
;
Fenfluramine
;
Fructose
;
Heart Diseases
;
Heart Valves
;
Obesity
;
Phentermine
;
Piperidines
;
Pyrazoles
;
Serotonin
;
United States Food and Drug Administration
;
Weight Loss
5.Recent Advances for Anti-Obesity Agents.
Journal of Korean Diabetes 2015;16(4):260-268
Obesity is one of the most significant risk factor for diabetes, cardiovascular disease, malignancy and other chronic diseases. The obesity and its associated conditions is one of the most urgent health concerns worldwide. Lifestyle modifications comprising diet modification, exercise, and behavior therapy are basic to the treatment for obesity. However, it has become apparent that lifestyle modifications alone will not be enough for many patients with obesity. Therefore, apractical approach includes consideration of pharmacotherapeutic options. Until 2012, orlistat was the only approved medication for long-term obesity management. In 2012, lorcaserin and phentermine/topiramate were approved by the USA Food and Drug Administration as new anti-obesity drugs, and in 2014, two additional medications were added, naltrexone/bupropion and liraglutide. This review discusses the different pharmacotherapeutic options for the treatment of obesity.
Anti-Obesity Agents*
;
Behavior Therapy
;
Cardiovascular Diseases
;
Chronic Disease
;
Food Habits
;
Humans
;
Life Style
;
Obesity
;
Risk Factors
;
United States Food and Drug Administration
;
Liraglutide
6.Pharmacotherapy for Obesity.
Journal of Menopausal Medicine 2014;20(3):90-96
Obesity is an important risk factor for metabolic disease and various cancers. Treatments of obesity include lifestyle intervention, pharmacotherapy, and bariatric surgery. If weight loss with lifestyle intervention is only modest, pharmacotherapy might be needed. Pharmacotherapy agents can be grouped by treatment period as short term or long term use agent. Several sympathomimetic drugs such as benzphetamine, diethylpropion, phendimetrazine and phentermine, are approved for short term treatment due to their safety issues. For long term treatment, orlistat, lorcaserin, and combination of phentermine/topiramate are approved by U.S. Food and Drug Administration (FDA). Orlistat partially blocks intestinal digestion of fat, therefore producing weight loss. Lorcaserin is a serotonin 2C receptor agonist. The combination of phentermine/topiramate produces a mean weight loss of 8-10 kg. Side effects of each drug are quite different. For obesity patient, side effects are important factor when choosing drugs. The goal of this article is to review currently available anti-obesity drugs.
Anti-Obesity Agents
;
Bariatric Surgery
;
Benzphetamine
;
Diethylpropion
;
Digestion
;
Drug Therapy*
;
Humans
;
Life Style
;
Metabolic Diseases
;
Obesity*
;
Phentermine
;
Receptor, Serotonin, 5-HT2C
;
Risk Factors
;
Sympathomimetics
;
United States Food and Drug Administration
;
Weight Loss
7.Behavioral Intervention and Anti-Obesity Drug Therapy.
Korean Journal of Medicine 2013;84(5):624-628
Obesity is associated with a reduction in life expectancy and an increase in mortality from cardiovascular diseases, cancer, and other causes. The U.S. Preventive Service Task Force (USPSTF) recommends screening all adults for obesity. Clinicians should offer or refer patients with a body mass index of 30 kg/m2 or higher to intensive, multicomponent behavioral interventions. Behavioral interventions can lead to a moderate weight loss and improvement in blood sugar and other risk factors for cardiovascular disease. Behavioral interventions decreased the incidence of diabetes diagnosis by about 50% over 2 to 3 years. Orlistat, phentermine, diethylpropion, phendimetrazine, mazindol have been approved as anti-obesity drugs by Korea Food and Drug Administration. The U.S. Food and Drug Administration approved lorcaserin and phentermine plus topiramate combination for treatment of obesity in 2012.
Adult
;
Advisory Committees
;
Anti-Obesity Agents
;
Benzazepines
;
Blood Glucose
;
Body Mass Index
;
Cardiovascular Diseases
;
Diethylpropion
;
Fructose
;
Humans
;
Incidence
;
Korea
;
Lactones
;
Life Expectancy
;
Mass Screening
;
Mazindol
;
Morpholines
;
Obesity
;
Phentermine
;
Risk Factors
;
United States Food and Drug Administration
;
Weight Loss
8.Anti-adipogenic effect of Artemisia annua in diet-induced-obesity mice model.
Hye Kyung BAEK ; Hyeji SHIM ; Hyunmook LIM ; Minju SHIM ; Chul Kyu KIM ; Sang Kyu PARK ; Yong Seok LEE ; Ki Duk SONG ; Sung Jo KIM ; Sun Shin YI
Journal of Veterinary Science 2015;16(4):389-396
Obesity has increased continuously in western countries during the last several decades and recently become a problem in developing countries. Currently, anti-obesity drugs originating from natural products are being investigated for their potential to overcome adverse effects associated with chemical drugs. Artemisinic acid, which was isolated from the well-known anti-malaria herb Artemisia annua (AA) L., was recently shown to possess anti-adipogenic effects in vitro. However, the anti-adipogenic effects of AA in animal models have not yet been investigated. Therefore, we conducted daily oral administration with AA water extract in a diet-induced obesity animal model and treated 3T3-L1 cells with AA to confirm the anti-adipogenic effects in the related protein expressions. We then evaluated the physiology, adipose tissue histology and mRNA expressions of many related genes. Inhibition of adipogenesis by the AA water extract was observed in vitro. In the animal model, weight gain was significantly lower in the AA treated group, but there were no changes in food intake volume or calories. Reductions in lipid droplet size and mRNA expression associated with adipogenesis were also observed in animal epididymal fat. This study is the first to report that AA has an anti-obese effects in vivo.
3T3-L1 Cells
;
Adipogenesis
;
Adipose Tissue
;
Administration, Oral
;
Animals
;
Anti-Obesity Agents
;
Artemisia annua*
;
Artemisia*
;
Biological Products
;
Developing Countries
;
Eating
;
Mice*
;
Models, Animal
;
Obesity
;
Physiology
;
RNA, Messenger
;
Water
;
Weight Gain
9.Supplementation of Fermented Barley Extracts with Lactobacillus Plantarum dy-1 Inhibits Obesity via a UCP1-dependent Mechanism.
Xiang XIAO ; Juan BAI ; Ming Song LI ; Jia Yan ZHANG ; Xin Juan SUN ; Ying DONG
Biomedical and Environmental Sciences 2019;32(8):578-591
OBJECTIVE:
We aimed to explore how fermented barley extracts with Lactobacillus plantarum dy-1 (LFBE) affected the browning in adipocytes and obese rats.
METHODS:
In vitro, 3T3-L1 cells were induced by LFBE, raw barley extraction (RBE) and polyphenol compounds (PC) from LFBE to evaluate the adipocyte differentiation. In vivo, obese SD rats induced by high fat diet (HFD) were randomly divided into three groups treated with oral gavage: (a) normal control diet with distilled water, (b) HFD with distilled water, (c) HFD with 800 mg LFBE/kg body weight (bw).
RESULTS:
In vitro, LFBE and the PC in the extraction significantly inhibited adipogenesis and potentiated browning of 3T3-L1 preadipocytes, rather than RBE. In vivo, we observed remarkable decreases in the body weight, serum lipid levels, white adipose tissue (WAT) weights and cell sizes of brown adipose tissues (BAT) in the LFBE group after 10 weeks. LFBE group could gain more mass of interscapular BAT (IBAT) and promote the dehydrogenase activity in the mitochondria. And LFBE may potentiate process of the IBAT thermogenesis and epididymis adipose tissue (EAT) browning via activating the uncoupling protein 1 (UCP1)-dependent mechanism to suppress the obesity.
CONCLUSION
These results demonstrated that LFBE decreased obesity partly by increasing the BAT mass and the energy expenditure by activating BAT thermogenesis and WAT browning in a UCP1-dependent mechanism.
3T3 Cells
;
Adipocytes
;
drug effects
;
physiology
;
Adipose Tissue, Brown
;
drug effects
;
physiology
;
Adipose Tissue, White
;
drug effects
;
physiology
;
Animal Feed
;
analysis
;
Animals
;
Anti-Obesity Agents
;
administration & dosage
;
metabolism
;
Cell Differentiation
;
drug effects
;
Diet
;
Fermentation
;
Hordeum
;
chemistry
;
Lactobacillus plantarum
;
chemistry
;
Male
;
Mice
;
Obesity
;
drug therapy
;
genetics
;
Plant Extracts
;
chemistry
;
Probiotics
;
administration & dosage
;
metabolism
;
Random Allocation
;
Rats
;
Rats, Sprague-Dawley
;
Uncoupling Protein 1
;
genetics
;
metabolism
10.Anti-obesity effects of Lysimachia foenum-graecum characterized by decreased adipogenesis and regulated lipid metabolism.
Jong Bae SEO ; Sung Sik CHOE ; Hyun Woo JEONG ; Sang Wook PARK ; Hyun Jung SHIN ; Sun Mi CHOI ; Jae Young PARK ; Eun Wook CHOI ; Jae Bum KIM ; Dong Seung SEEN ; Jae Yeon JEONG ; Tae Gyu LEE
Experimental & Molecular Medicine 2011;43(4):205-215
Lysimachia foenum-graecum has been used as an oriental medicine with anti-inflammatory effect. The anti-obesity effect of L. foenum-graecum extract (LFE) was first discovered in our screening of natural product extract library against adipogenesis. To characterize its anti-obesity effects and to evaluate its potential as an anti-obesity drug, we performed various obesity-related experiments in vitro and in vivo. In adipogenesis assay, LFE blocked the differentiation of 3T3-L1 preadipocyte in a dose-dependent manner with an IC50 of 2.5 microg/ml. In addition, LFE suppressed the expression of lipogenic genes, while increasing the expression of lipolytic genes in vitro at 10 microg/ml and in vivo at 100 mg/kg/day. The anti-adipogenic and anti-lipogenic effect of LFE seems to be mediated by the inhibition of PPARgamma and C/EBPalpha expression as shown in in vitro and in vivo, and the suppression of PPARgamma activity in vitro. Moreover, LFE stimulated fatty acid oxidation in an AMPK-dependent manner. In high-fat diet (HFD)-induced obese mice (n = 8/group), oral administration of LFE at 30, 100, and 300 mg/kg/day decreased total body weight gain significantly in all doses tested. No difference in food intake was observed between vehicle- and LFE-treated HFD mice. The weight of white adipose tissues including abdominal subcutaneous, epididymal, and perirenal adipose tissue was reduced markedly in LFE-treated HFD mice in a dose-dependent manner. Treatment of LFE also greatly improved serum levels of obesity-related biomarkers such as glucose, triglycerides, and adipocytokines leptin, adiponectin, and resistin. All together, these results showed anti-obesity effects of LFE on adipogenesis and lipid metabolism in vitro and in vivo and raised a possibility of developing LFE as anti-obesity therapeutics.
3T3-L1 Cells
;
Adipogenesis/*drug effects
;
Adipose Tissue/drug effects/metabolism
;
Adipose Tissue, White
;
Animals
;
Anti-Obesity Agents/administration & dosage/pharmacology/*therapeutic use
;
Body Weight/drug effects
;
CCAAT-Enhancer-Binding Protein-alpha/genetics
;
Cell Differentiation/drug effects
;
Eating/drug effects
;
Fatty Acids/metabolism
;
Gene Expression/drug effects
;
Lipid Metabolism/*drug effects
;
Lipids
;
Lipogenesis/drug effects
;
Mice
;
Mice, Inbred C57BL
;
Obesity/prevention & control
;
PPAR gamma/antagonists & inhibitors/genetics
;
Plant Extracts/*pharmacology
;
Plants, Medicinal
;
Primulaceae/*chemistry